...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: And we wait.....

I suspect the Zenith team is working diligently and as hard as they can do complete the PP deal, I am hoping once it is completed we might hear about an IPO if thats the direction they want to go.  ......

Share
New Message
Please login to post a reply